Diamyd Medical AB (publ) (STO:DMYD.B)
Sweden · Delayed Price · Currency is SEK 1.048
+0.034 (3.35%)
Oct 13, 2026, 5:22 PM CET
Diamyd Medical AB Income Statement
Financials in millions SEK. Fiscal year is September - August.
Millions SEK. Fiscal year is Sep - Aug.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 |
Operating Revenue | 0.48 | 0.13 | 0.13 | 0.55 | 0.45 |
Other Revenue | -0 | - | - | - | - |
| 0.48 | 0.13 | 0.13 | 0.55 | 0.45 | |
Revenue Growth | 266.92% | 0% | -76.19% | 20.26% | 79.45% |
Cost of Revenue | 2.76 | 3.84 | 3.71 | 3.63 | 4.4 |
Gross Profit | -2.28 | -3.71 | -3.58 | -3.09 | -3.95 |
Selling, General & Admin | 70.83 | 56.55 | 44.79 | 39.7 | 31.93 |
Research & Development | 180.13 | 119.5 | 96.48 | 69.91 | 75.57 |
Other Operating Expenses | -2.69 | -3.03 | -3.16 | -1.72 | -0.89 |
Operating Expenses | 255.29 | 179.53 | 143.69 | 112.76 | 110.99 |
Operating Income | -257.58 | -183.23 | -147.27 | -115.85 | -114.94 |
Interest Expense | -3.52 | - | -0.01 | -0 | -0.25 |
Interest & Investment Income | 6.42 | 2.34 | 3.75 | 1.05 | 0.07 |
Earnings From Equity Investments | - | - | 6.12 | -4.96 | -3.24 |
Currency Exchange Gain (Loss) | - | 4.16 | 0.12 | 3.68 | 8.19 |
Other Non Operating Income (Expenses) | - | -0 | -0 | 0 | -0 |
EBT Excluding Unusual Items | -254.68 | -176.73 | -137.3 | -116.07 | -110.17 |
Gain (Loss) on Sale of Investments | -0.91 | 6.96 | -9.14 | - | 6.65 |
Asset Writedown | - | - | -5.41 | - | - |
Pretax Income | -255.59 | -169.78 | -151.85 | -116.07 | -103.52 |
Net Income | -255.59 | -169.78 | -151.85 | -116.07 | -103.52 |
Net Income to Common | -255.59 | -169.78 | -151.85 | -116.07 | -103.52 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 145 | 113 | 95 | 78 | 77 |
Shares Outstanding (Diluted) | 145 | 113 | 95 | 78 | 77 |
Shares Change | 29.02% | 18.81% | 20.98% | 2.29% | 9.65% |
EPS (Basic) | -1.76 | -1.51 | -1.60 | -1.48 | -1.35 |
EPS (Diluted) | -1.76 | -1.51 | -1.60 | -1.48 | -1.35 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 |
Free Cash Flow | -196.3 | -179.73 | -137.21 | -122.4 | -127.87 |
Free Cash Flow Per Share | -1.35 | -1.60 | -1.45 | -1.56 | -1.67 |
Operating Margin | -53999.37% | -140949.23% | -113287.69% | -21217.22% | -25316.30% |
Profit Margin | -53583.44% | -130597.69% | -116807.69% | -21258.79% | -22801.10% |
Free Cash Flow Margin | -41153.67% | -138254.61% | -105543.08% | -22418.32% | -28165.42% |
EBITDA | -250.55 | -176.73 | -141.69 | -110.98 | -110.55 |
D&A For EBITDA | 7.02 | 6.5 | 5.58 | 4.87 | 4.38 |
EBIT | -257.58 | -183.23 | -147.27 | -115.85 | -114.94 |
Revenue as Reported | 4.68 | 5.02 | 4.36 | 3.75 | 2.58 |